
Escient Pharmaceuticals
AcquiredSan Diego, United States · Founded 2018
- Headquarters
- San Diego, California
- Employees
- 51–200
- Founded
- 2018
- Business Model
- B2B
- Website
- escientpharma.com
- Last Round
- Series CNov 2022
- Rounds
- 3
- Acquired by
- IncyteApr 2024
About
Escient Pharmaceuticals was a San Diego-based clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for mast cell-mediated disorders including chronic urticaria, cholestatic pruritus, and atopic dermatitis. Its lead program EP262 targeted MRGPRX2 receptors. Escient was acquired by Incyte Corporation for $750 million in 2024.
Summary
Escient Pharmaceuticals is a Pharmaceutical company based in San Diego, United States, founded in 2018. Its most recent funding was a Series C round in Nov 2022. Investors include NEA, Incyte and Abingworth Bioventures.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Apr 2024
Sign up to see all 4 rounds
Series A through Acquisition — per-round amounts, valuations, and who invested in each round.
Investors
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/escient-pharmaceuticals"><img src="https://indexed.vc/api/badge/company/escient-pharmaceuticals" alt="Escient Pharmaceuticals on Indexed.vc" width="260" height="76" /></a>

